Recent Research Analysts’ Ratings Updates for Hims & Hers Health (HIMS)

A number of firms have modified their ratings and price targets on shares of Hims & Hers Health (NYSE: HIMS) recently:

• 2/10/2026 – Hims & Hers Health was given a new $31.00 price target on by analysts at Deutsche Bank Aktiengesellschaft. They now have a “hold” rating on the stock.
• 2/9/2026 – Hims & Hers Health had its price target lowered by analysts at TD Cowen from $30.00 to $20.00. They now have a “hold” rating on the stock.
• 2/9/2026 – Hims & Hers Health had its price target lowered by analysts at Citigroup Inc. from $30.00 to $16.50. They now have a “sell” rating on the stock.
• 2/9/2026 – Hims & Hers Health had its price target lowered by analysts at Bank of America Corporation from $26.00 to $21.00. They now have an “underperform” rating on the stock.
• 2/2/2026 – Hims & Hers Health had its price target lowered by analysts at BTIG Research from $85.00 to $60.00. They now have a “buy” rating on the stock.
• 1/19/2026 – Hims & Hers Health was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 1/12/2026 – Hims & Hers Health is now covered by analysts at Evercore Inc. They set an “in-line” rating and a $33.00 price target on the stock.
• 1/5/2026 – Hims & Hers Health had its “sell” rating reaffirmed by analysts at Citigroup Inc..
• 12/29/2025 – Hims & Hers Health had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Hims & Hers Health had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Irene Becklund sold 8,411 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the completion of the sale, the insider owned 2,126 shares in the company, valued at $78,045.46. This trade represents a 79.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Chi sold 13,750 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the transaction, the chief operating officer directly owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. This trade represents a 4.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 82,963 shares of company stock worth $2,944,621. Company insiders own 13.71% of the company’s stock.

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.